We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$310M
AUM Growth
+$201M
Cap. Flow
+$194M
Cap. Flow %
62.66%
Top 10 Hldgs %
99.78%
Holding
12
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
REAL icon
The RealReal
REAL
+$194M
2
GKOS icon
Glaukos
GKOS
+$332K

Top Sells

Rank Stock Value
1
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$39.1K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 62.56%
2 Healthcare 37.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REAL icon
1
The RealReal
REAL
$1.4B
$194M 62.56%
+6,704,080
New +$194M
AVDR
2
DELISTED
Avedro, Inc Common Stock
AVDR
$53.9M 17.39%
2,742,239
– –
MGNX icon
3
MacroGenics
MGNX
$254M
$18.2M 5.89%
1,074,316
– –
STIM icon
4
Neuronetics
STIM
$126M
$12.9M 4.16%
1,030,689
– –
KALV
5
DELISTED
KalVista Pharmaceuticals
KALV
$8.61M 2.78%
388,766
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$8.11M 2.62%
25,497
-113
-0.4% -$39.1K
AGTC
7
DELISTED
Applied Genetic Technologies Corporation
AGTC
$5.52M 1.78%
1,455,904
– –
VERO
8
DELISTED
Venus Concept
VERO
$3.27M 1.06%
2,164
– –
HIND
9
Vyome Holdings
HIND
$14M
– –
0
– –
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$2.28M 0.74%
67,841
– –
GKOS icon
11
Glaukos
GKOS
$8.92B
$602K 0.19%
7,995
+4,633
+138% +$332K
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.36B
$82K 0.03%
8,293
– –

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q2 2019 Portfolio in Review

As of Q2 2019, InterWest Venture Management held 12 positions worth $310M, up 184% from $109M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management deployed $194M of net new capital in Q2 2019, opening 1 new position and adding to 1 existing holding. Its largest new stake was The RealReal: 6,704,080 shares worth $194M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 63% of assets, followed by Healthcare.

On the sell side, the largest reduction was Eiger BioPharmaceuticals, Inc., an estimated $39.1K trimmed.

  • InterWest Venture Management's largest Q2 2019 buy was The RealReal: 6,704,080 shares worth $194M.
  • InterWest Venture Management added most to Glaukos in Q2 2019, an estimated $332K increase.
  • InterWest Venture Management's biggest Q2 2019 reduction was Eiger BioPharmaceuticals, Inc., cutting an estimated $39.1K.
  • InterWest Venture Management's ten largest holdings make up 100% of its $310M portfolio in Q2 2019.
  • InterWest Venture Management opened 1 new position and closed 0 in Q2 2019.
  • InterWest Venture Management's portfolio value rose 184% quarter-over-quarter to $310M.

Based on InterWest Venture Management's 13F filing for Q2 2019, filed 29 Jul 2019.